Orthocell Secures US Department of Defense Approval for Remplir Collagen Nerve Wrap
Orthocell has gained approval for its Remplir nerve repair device across U.S. Department of Defence and Veterans Affairs hospital networks, expanding access to more than 220 military and veteran care facilities as it uses its distributor network to drive adoption in trauma-focused surgical settings.
Key Points
- Orthocell has secured approval for Remplir to be used across 51 DoD military hospitals and 170 VA medical centers in the United States.
- The company plans to use its existing U.S. distributor network, which covers 17 states, to target military and VA surgeons within those systems.
- Orthocell says Remplir has also been used in 23 surgical procedures on injured soldiers in Ukraine, supporting its relevance for traumatic nerve injuries seen in military care.
Expanded U.S. hospital access
Orthocell has secured approval for Remplir to be used across the United States Department of Defense (DoD) and Veterans Affairs (VA) hospital networks. The approval gives the company access to about 51 DoD military hospitals and 170 VA medical centers.
Stay Ahead in Regenerative Medicine
Thanks! Your signup has been saved.
Orthocell had already secured 32 Value Analysis Committee approvals covering more than 115 hospitals, with another 57 applications still pending approval.
Commercial rollout
Orthocell will use its existing U.S. distributor network to target military and VA surgeons operating within these hospital systems. The company said its distributor network currently covers 17 states, with a significant portion of these facilities falling within that footprint.
The company also said the approval comes as it is seeing increasing commercialization and revenue momentum in the U.S. market.
Ukraine experience
Orthocell said Remplir was recently used in 23 surgical procedures on injured soldiers in Ukraine, including both primary and secondary nerve repair applications, and it showed good portability, ease of use, and suitability for traumatic injuries commonly seen in military settings.
Want to keep up on regenerative medicine? Get the weekly newsletter here.
Similar stories
Made Scientific Selected to Manufacture Columbia University’s NOVAKnee, a 3D Printed Knee Replacement Made of Stem Cells and Scaffolds
BioStem Technologies Receives 5 Patents for Placental Allografts
Kangstem Publishes Promising Phase 1 Results for Cord-Blood Derived Stem Cell Therapy in Knee Osteoarthritis, Post-MRI Data Suggest Potential Cartilage Regeneration
Royal Biologics and Jellagen Bringing Jellyfish-Derived Collagen Type Zero to the US Regenerative Medicine MarketEditor’s Picks
Century Therapeutics Reports Sustained Glucose Control With iPSC-Derived Islets in Diabetic Mice, IND Soon
Umbilical Cord Mesenchymal Stem Cell Injections Lower Pain Scores More Than Hyaluronate in 50-Patient Severe Knee Osteoarthritis Trial
Stempeutics Nabs US Patent for Osteoarthritis Treatment Combining Bone Marrow Stem Cells and Hyaluronic Acid
Inside Cellular Intelligence: The Zuck-Backed AI Company That Acquired Novo’s Parkinson’s Cell Therapy
